

## SUMMARY PRODUCT PROFILE FOR HPV VACCINES

Updated as of 22 February 2017

<b>Vaccine group<sup>1</sup></b>	HPV		
<b>Vaccine type<sup>1</sup></b>	HPV Bivalent	HPV Quadrivalent	HPV Nonavalent <sup>i</sup>
<b>Serotypes<sup>1</sup></b>	HPV types 16 and 18	HPV types 16 and 18 and, for anogenital warts, HPV 6 and 11	HPV types 16,18, 31,33, 45, 52, 58 and, for anogenital warts, HPV 6 and 11
<b>Presentation (doses per container, primary container type, pharmaceutical form)<sup>1</sup></b>	2 dose vial, liquid	1 dose vial, liquid	1 dose vial, liquid
<b>Routine and/or campaign</b>	Routine	Routine	Routine
<b>WHO recommended vaccine schedule</b>	For girls 9-14 years old, a 2-dose schedule (0.5 mL), the second dose at least 6 months from the first, with exceptions for special populations	For girls 9-14 years old, a 2-dose schedule (0.5 mL), the second dose at least 6 months from the first, with exceptions for special populations	For girls 9-14 years old, a 2-dose schedule (0.5 mL), the second dose at least 6 months from the first, with exceptions for special populations
<b>2017 price per dose (USD)<sup>2</sup></b>	\$4.60	\$4.50	Up to \$6.90*
<b>Doses per fully immunised person<sup>**</sup></b>	2	2	2
<b>Indicative wastage rate<sup>3</sup></b>	10%	5%	5%
<b>Manufacturer<sup>1</sup></b>	GlaxoSmithKline Biologicals S.A.	Merck Sharp & Dohme Corp.	Merck Sharp & Dohme Corp.
<b>Vaccine trade name<sup>1</sup></b>	Cervarix™ <sup>4</sup>	Gardasil®	Gardasil 9®
<b>Administration<sup>1</sup></b>	Intramuscular	Intramuscular	Intramuscular
<b>Shelf-life<sup>1</sup></b>	48 months at 2 - 8 °C	36 months at 2 - 8 °C	36 months at 2 - 8 °C
<b>Use in controlled temperature chain (CTC)</b>		up to 3 days at ambient temperatures not exceeding 42°C	
<b>Cold chain volume per dose (cm<sup>3</sup>)<sup>1</sup></b>	Carton of 1 vial : 28.8 cm <sup>3</sup> Carton of 10 vials : 5.7 cm <sup>3</sup> Carton of 100 vials : 4.8 cm <sup>3***</sup>	Carton of 1 vial: 75 cm <sup>3</sup> Carton of 10 vials: 15 cm <sup>3***</sup>	Carton of 10 vials: 15cm <sup>3</sup>
<b>Vaccine vial monitor type<sup>1</sup></b>	Type 30	Type 30	TBC

<sup>1</sup> Source: WHO PQ webpage: WHO updates these webpages as new information on products becomes available. Please refer for these pages for the most up-to-date information.

2 Source: Gavi Price Forecast, June 2016

3 Source: Review of WHO indicative vaccine wastage rate assumptions, 2011

4 For more information see: [www.who.int/immunization\\_standards/vaccine\\_quality/cervarix\\_pqnote\\_2dose\\_2013](http://www.who.int/immunization_standards/vaccine_quality/cervarix_pqnote_2dose_2013)

<sup>i</sup> This presentation is not yet prequalified by WHO.

\* Estimate. Maximum indicative price reflecting the maximum historic vaccine expenditure per immunised girl for HPV.

\*\*Estimated assuming 2 doses for fully immunized child. Special populations will need 3 doses. See WHO position paper on HPV vaccines, 2014 [http://www.who.int/entity/wer/2014/wer8943.pdf?ua=1]

\*\*\*This secondary packaging is procured for Gavi countries by UNICEF.